文章：

胃癌诊疗一体化策略：体外与体内研究综述

Theranostic Approaches for Gastric Cancer: An Overview of In Vitro and In Vivo Investigations

原文发布日期：28 September 2024

DOI: 10.3390/cancers16193323

类型: Article

开放获取: 是

英文摘要：

Gastric cancer (GC) is the second most common cause of cancer-related death worldwide and a serious public health concern. This high death rate is mostly caused by late-stage diagnoses, which lead to poor treatment outcomes. Radiation immunotherapy and targeted therapies are becoming increasingly popular in GC treatment, in addition to surgery and systemic chemotherapy. In this review, we have focused on both in vitro and in vivo research, which presents a summary of recent developments in targeted therapies for gastric cancer. We explore targeted therapy approaches, including integrin receptors, HER2, Claudin 18, and glutathione-responsive systems. For instance, therapies targeting the integrin receptors such as the αvβ3 and αvβ5 integrins have shown promise in enhancing diagnostic precision and treatment efficacy. Furthermore, nanotechnology provides novel approaches to targeted drug delivery and imaging. These include glutathione-responsive nanoplatforms and cyclic RGD peptide-conjugated nanoparticles. These novel strategies seek to reduce systemic toxicity while increasing specificity and efficacy. To sum up, the review addresses the significance of personalized medicine and advancements in gastric cancer-targeted therapies. It explores potential methods for enhancing gastric cancer prognosis and treatment in the future.

摘要翻译： 

胃癌是全球癌症相关死亡的第二大常见原因，是一个严重的公共卫生问题。高死亡率主要源于晚期诊断，导致治疗效果不佳。除了手术和全身化疗外，放射免疫疗法和靶向疗法在胃癌治疗中日益受到重视。本综述聚焦于体外和体内研究，总结了胃癌靶向治疗的最新进展。我们探讨了包括整合素受体、HER2、Claudin 18以及谷胱甘肽响应系统在内的靶向治疗方法。例如，针对αvβ3和αvβ5等整合素受体的疗法在提高诊断精度和治疗效果方面显示出潜力。此外，纳米技术为靶向药物递送和成像提供了新途径，包括谷胱甘肽响应型纳米平台和环状RGD肽偶联纳米颗粒。这些新策略旨在降低全身毒性，同时提高特异性和疗效。总之，本综述阐述了精准医疗的重要性以及胃癌靶向治疗的进展，并探讨了未来改善胃癌预后和治疗的潜在方法。

原文链接：

Theranostic Approaches for Gastric Cancer: An Overview of In Vitro and In Vivo Investigations